Biosimilars in Focus for Retina Practices

Please join us on April 26, 2023 | 6:00 p.m. CT

More retina biosimilars are entering the pipeline, including last year’s first interchangeable product across all five indications. Don’t miss this upcoming opportunity to join our retina-focused discussion on Wednesday, April 26 to gain a better understanding of the foundational science behind biosimilars and the evolving payer landscape.

Hear from clinical and business experts:

Tim Ho, PharmD, BCOP
Regional Clinical Consultant, McKesson

Christine Kern, MBA
Regional Director Managed Care Contracting, McKesson

Key takeaways:

  • Understand the difference between reference drugs and biosimilars as well as the FDA’s position and guidelines
  • Learn about the clinical efficacy of biosimilar therapies
  • Address reimbursement hurdles
  • Learn how to develop a payer strategy
  • Prepare for biosimilars at your retina practice with confidence